Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Yervoy
Yervoy
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer
BioSpace
Fri, 12/8/23 - 10:00 am
Bristol Myers Squibb
Opdivo
Yervoy
colorectal cancer
metastatic colorectal cancer
clinical trials
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Sat, 03/18/23 - 03:37 pm
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Sat, 03/18/23 - 03:35 pm
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo
Fierce Pharma
Tue, 01/24/23 - 06:31 pm
Bristol Myers Squibb
legal
AstraZeneca
Imjudo
Yervoy
cancer
patents
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Thu, 12/1/22 - 07:11 pm
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
Mon, 09/12/22 - 10:57 am
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Mon, 07/11/22 - 05:48 pm
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy
Fierce Pharma
Thu, 09/16/21 - 10:56 am
Bristol Myers Squibb
Opdivo
Yervoy
kidney cancer
ESMO
Bristol Myers rolls out 3-year data mesothelioma data for Opdivo/Yervoy in first look at ESMO slate
Endpoints
Mon, 09/13/21 - 10:32 am
Bristol Myers Squibb
Opdivo
Yervoy
mesothelioma
Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
Fierce Biotech
Wed, 02/24/21 - 10:57 am
Xilio Therapeutics
funding
immunotherapy
clinical trials
cancer
oncology
Yervoy
Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy
BioSpace
Mon, 02/1/21 - 11:12 pm
Merck
Keytruda
Bristol-Myers Squibb
Yervoy
non-small cell lung cancer
WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer
Fierce Pharma
Sat, 01/30/21 - 11:32 pm
WCLC
Keytruda
Yervoy
Merck
Bristol-Myers Squibb
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Endpoints
Tue, 11/10/20 - 10:45 am
Merck
Keytruda
Yervoy
clinical trials
non-small cell lung cancer
Jounce shares crash after it abandons immunotherapy combination trial
Pharmaforum
Tue, 11/3/20 - 10:24 am
Jounce Therapeutics
non-small cell lung cancer
Bristol-Myers Squibb
Yervoy
Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma
Motley Fool
Sun, 10/4/20 - 10:59 pm
Bristol-Myers Squibb
FDA
Opdivo
Yervoy
mesothelioma
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Fierce Pharma
Sat, 08/8/20 - 10:46 pm
WCLC
lung cancer
mesothelioma
Bristol-Myers Squibb
Opdivo
Yervoy
clinical trials
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
Thu, 06/25/20 - 08:36 pm
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
FDA approval tracker: several early decisions in May
EP Vantage
Wed, 06/3/20 - 10:24 am
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
Pharmaceutical Business Review
Wed, 05/27/20 - 10:30 am
Bristol-Myers Squibb
Opdvio
Yervoy
metastatic non-small cell lung cancer
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Thu, 05/14/20 - 10:56 pm
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Pages
1
2
3
4
5
6
7
next ›
last »